Clinical evaluation of cisplatin sensitivity of germline polymorphisms in neoadjuvant chemotherapy for urothelial cancer
PH O'Donnell, S Alanee, KL Stratton… - Clinical genitourinary …, 2016 - Elsevier
Background Level 1 evidence has demonstrated increased overall survival with cisplatin-
based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer.
Usage remains low, however, in part because neoadjuvant chemotherapy will not be
effective for every patient. To identify the patients most likely to benefit, we evaluated
germline pharmacogenomic markers for association with neoadjuvant chemotherapy
sensitivity in 2 large cohorts of patients with urothelial cancer. Patients and Methods Patients …
based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer.
Usage remains low, however, in part because neoadjuvant chemotherapy will not be
effective for every patient. To identify the patients most likely to benefit, we evaluated
germline pharmacogenomic markers for association with neoadjuvant chemotherapy
sensitivity in 2 large cohorts of patients with urothelial cancer. Patients and Methods Patients …
以上显示的是最相近的搜索结果。 查看全部搜索结果